Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Protara Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 40 | 36 | −4 |
| Shares | 7.11M | 6.31M | −799.0K (−11.2%) |
| Value | $69.3M | $43.7M | −$25.6M (−36.9%) |
New holders (7)
Institutions that held Protara Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bridgeway Capital Management, LLC | 112,500 | $779.0K | 0.01% |
| Virtu Financial LLC | 17,130 | $119.0K | 0.01% |
| Jump Financial, LLC | 14,500 | $100.0K | 0.01% |
| Trexquant Investment LP | 12,454 | $86.0K | 0.01% |
| Advisor Group Holdings, Inc. | 2,600 | $18.0K | 0.00% |
| Royal Bank of Canada | 664 | $4.00K | 0.00% |
| American Portfolios Advisors | 100 | $692 | 0.00% |
Sold out (11)
Institutions that held Protara Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Rock Springs Capital Management LP | 693,542 | $6.75M |
| Franklin Resources Inc | 350,010 | $3.41M |
| Ergoteles LLC | 17,700 | $172.0K |
| Jane Street Group, LLC | 13,678 | $133.0K |
| HRT Financial LP | 12,151 | $118.0K |
| Tower Research Capital LLC (TRC) | 1,548 | $15.0K |
| Retirement Group, LLC | 500 | $5.00K |
| Panagora Asset Management Inc | 55 | $1.00K |
| UBS Group AG | 99 | $1.00K |
| New York State Common Retirement Fund | 29 | $0 |
| Citigroup Inc | 15 | $0 |